Clinical trial · Observational
Eye Plaque Brachytherapy for Ocular Melanoma
Prospective Registry of Ocular Melanoma Eye Plaque brachyTherapy Patients (PROMPT)
NCT06432660CI-TRIAL-00102655PROMPTactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. The goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related to radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ocular Melanoma | Ocular Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ocular Melanoma
- description
- Patients 18 years of age or older with unilateral primary choroidal melanoma
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- Percentage of participants with no disease recurrence within the radiation therapy field.
- timeFrame
- 5 years
- description
- Number of disease free participants expressed as a percentage of the total number of participants enrolled
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years of age or older with unilateral primary choroidal melanoma * Patients with diagnosis of small or medium ocular melanomas amenable to plaque brachytherapy (as determined by treating ocular oncologist). Typically this would include tumors with apical height ≤10mm and basal diameter ≤16mm (small and medium tumors per COMS (Collaborative Ocular Melanoma Study) * Patients with no clinical evidence of metastatic disease as confirmed by negative staging imaging (CT, MRI, and/or ultrasound) * Patients with best-corrected visual acuity in the fellow eye of 20/200 or better * Patients must be treated with IsoAid Eye Physics eye plaques Exclusion Criteria: * Patients whose tumors are circumferential around the optic disc and cannot be adequately covered by the prescription dose are ineligible. * Similarly, patients with extrascleral tumor extension detected during echography or clinical exam, diffuse, ring or multifocal tumors that cannot be encompassed in a single episcleral plaque or tumors judged to be predominantly ciliary body or iris melanoma will be considered ineligible * Previous treatment for ocular melanoma in either eye or treatment of any condition secondary to the tumor are ineligible. * Patients with a history of other primary or metastatic cancers are not eligible, except for non-melanotic skin cancers * Patients with extraocular disease
References
Publications (1)
- BACKGROUNDMeltsner SG, Rodrigues A, Materin MA, Kirsch DG, Craciunescu O. Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience. J Appl Clin Med Phys. 2023 May;24(5):e13902. doi: 10.1002/acm2.13902. Epub 2023 Jan 13. PMID 36637797